12 results about "Ecdysterone" patented technology

The present application provides a kind of Echinops formula granule quality detection method, including the thin layer identification of Echinops formula granule, characteristic map construction and β-ecdysterone content determination, the content standard of formula granule is limited to every 1g contains β-ecdysterone 3.5~14.4mg, thin layer identification is identified using thin layer chromatography, characteristic map construction and β-ecdysterone content determination are all using liquid chromatography method.The quality detection method of Echinops formula granule of the present application, by the detection of thin layer identification, characteristic map construction and β-ecdysterone content determination to assess the quality of Echinops formula granule, can comprehensively reflect the inherent quality of formula granule and better control the quality of Echinops formula granule.

The application provides a kind of composition for relieving fatigue and its preparation method, belong to relieving fatigue composition technical field.The composition for relieving fatigue of the application includes the following raw materials by mass concentration: Brazilian ginseng-guarana composite water extract 60%-70%, taurine 1%-2%, tea polyphenol 0.2%-0.4%, inositol 0.8%-1.2%, maltitol 1%-1.5%, erythritol 0.5%-1%, stevioside 0.05%-0.1%, citric acid 0.01%-0.02%, malic acid 0.01%-0.02%, vitamin C 0.1%-0.3%, xanthan gum 0.08%-0.12%, and the balance is water.In the composition of the application, Brazilian ginseng-guarana composite water extract provides ecdysterone, caffeine and other core substances, laying the foundation for anti-fatigue;Taurine cooperates to remove lactic acid and reduce serum urea accumulation, inositol regulates energy homeostasis, tea polyphenol and vitamin C strengthen antioxidant protection, and each component plays a synergistic anti-fatigue effect through complementation, and the active ingredients are stable, low-calorie, and excellent in taste.

The invention discloses a sterone compound derived from achyranthes bidentata as well as a preparation method and application of the sterone compound. Belongs to the technical field of biological medicine. The invention aims to solve various side effects and defects of the existing medicine for treating glucocorticoid-induced osteoporosis in long-term use. The molecular formula of the compound (SSA) is C33H48O9, the compound (SSA) has a beta-ecdysterone skeleton, and acetal type 5-hydroxymethylfurfural groups are introduced at the positions of side chains C20 and C22. SSA has a remarkable protection effect in a DEX-induced osteoblast injury model, can improve cell viability decline and G1 phase retardation caused by glucocorticoid, and recovers osteogenic differentiation and mineralization ability. The SSA effectively reverses the inhibition effect of DEX on osteoblasts by activating a Wnt / beta-catenin signal channel and up-regulating the expression of RUNX2. SSA has a remarkable anti-osteoporosis function potential.

The invention relates to an anti-wrinkle composition, application thereof and cosmetics, the anti-wrinkle composition comprises ginsenoside CK and low-molecular-weight sodium hyaluronate, the mass ratio of the ginsenoside CK to the low-molecular-weight sodium hyaluronate is 1: (5-100), and the molecular weight of the low-molecular-weight sodium hyaluronate does not exceed 5000 Daltons. The anti-wrinkle composition has the beneficial effects that the usage amount of Ectoine and rare ginsenoside CK can be reduced, so that the cost is saved, and meanwhile, an excellent anti-wrinkle effect is realized.

Provided are an eye repair composition and use thereof. The eye repair composition comprises ecdysterone, a fermented product of Tibetan kefir grains, and heparin sodium. The composition consisting of the three components of ecdysterone, fermented product of Tibetan kefir grains, and heparin sodium has effects on skin, especially skin around the eyes, in improving skin brightness, reducing the periocular melanin content, and eliminating dark circles.

The application discloses ecdysterone-low molecular weight fructan composite microspheres with fat-reducing and muscle-increasing functions, and a preparation method and application thereof, and belongs to the technical field of biological medicine and functional food. The composite microspheres have a core-shell structure, the inner core is a calcium alginate gel, the outer shell is chitosan, the inner core co-encapsulates ecdysterone and low molecular weight fructan, and the mass ratio of the two is 0.8-1.2:1. The preparation adopts a liquid drop microfluidic technology combined with an internal gelation method to form the inner core, and adopts a post-crosslinking method to coat the outer shell. The composite microspheres are regular in shape, uniform in particle size, high in encapsulation rate, good in stability, excellent in pH response slow-release and anti-degradation characteristics in the gastrointestinal tract. In-vivo pharmacological experiments prove that the composite microspheres can reduce the body weight and body fat rate of obese mice, increase the lean meat content and muscle strength, realize synergistic effects of fat reduction and muscle increase, and can be used for preparing drugs or functional food for improving obesity-related muscle loss, low-muscle obesity and related metabolic syndrome.

The present invention relates to a synergistic composition for the improvement of compromised muscle health and management of sarcopenia. In particular, the invention provides a composition comprising ecdysterone, calcium hydroxy methylbutyrate, and selenium, wherein the constituents act synergistically to promote enhancement of skeletal muscle mass, muscular strength, and functional physical performance. Sarcopenia is a progressive and degenerative condition characterized by the loss of skeletal muscle mass and strength, commonly associated with aging or chronic disease and is recognized as a major contributor to increased risk of falls, mobility limitations, physical disability and elevated healthcare burden. The composition disclosed herein offers a comprehensive therapeutic approach for the prevention, delay or treatment of sarcopenia and related muscle-wasting disorders. The composition is formulated for oral administration and may be presented in various dosage forms including but not limited to powder, tablet, capsule, and syrup. The oral formulation facilitates user compliance and effective systemic delivery, thereby providing a practical and efficacious intervention for mitigating skeletal muscle deterioration and its associated physiological and functional impairments.

The application discloses application of paris polyphylla extract in inhibition of melanin transfer and cosmetics, and belongs to the technical field of cosmetics. The paris polyphylla extract contains β-ecdysterone, and the β-ecdysterone can inhibit melanin transfer, thereby achieving a whitening effect. The cosmetics containing the paris polyphylla extract have good whitening effect.

The application discloses a quality detection method of a Yishen Qingli Huoxue recipe, which comprises preparation of a test sample solution, preparation of a standard solution, preparation of a standard curve and content determination. The application screens an optimal test sample preparation method, a preparation method of a control sample and optimal chromatographic conditions and mass spectrometric analysis conditions through a large number of experiments, and establishes a content determination method of the Yishen Qingli Huoxue recipe, which can simultaneously determine the contents of 11 compounds with different structural types, such as resveratrol, rhein, formononetin, aloe-emodin, emodin, chlorogenic acid, polydatin, astilbin, hyperoside, calycosin-7-glucoside and beta-ecdysterone. The method is favorable for comprehensively monitoring the quality of the Yishen Qingli Huoxue recipe and guaranteeing clinical curative effects. Moreover, the method has the advantages of good stability, high accuracy, good repeatability and high precision.

The invention relates to a method for constructing HPLC characteristic chromatograms of a Yumai decoction reference sample, two sets of HPLC methods are adopted to comprehensively characterize component characteristics of four medicines in a Yumai decoction prescription, the first set of HPLC characteristic chromatogram determines 10 characteristic peaks, and the first set of HPLC characteristic chromatogram belongs to six characteristic peaks of the medicine flavor of prepared rehmannia root, and the second set of HPLC characteristic chromatogram belongs to six characteristic peaks of the medicine flavor of Yumai decoction. The components are respectively catalpol, adenosine, 5-hydroxymethylfurfural, rehmannia D, verbascoside and isoacteoside; the rhizoma anemarrhenae has three characteristic peaks, namely neomangiferin, mangiferin and isomangiferin; the first set of HPLC characteristic chromatogram determines five characteristic peaks which belong to beta-ecdysterone, the second set of HPLC characteristic chromatogram determines five characteristic peaks which belong to five characteristic peaks of radix ophiopogonis, and two peaks of the characteristic peaks are identified to be methylophiopogonanone A and methylophiopogonanone B respectively; the two sets of specific chromatogram methods established by the invention have good performance and better pertinence, can comprehensively characterize the component characteristics of the four medicines in the Yumai decoction prescription, and can effectively monitor the quality of the Yumai decoction preparation.

The present invention relates to a synergistic bioactive composition for improving compromised muscle health and for the prevention, management or treatment of sarcopenia. The composition comprises ecdysterone, curcuminoids, and selenium, wherein the combination of these active agents exhibits a synergistic effect in enhancing muscle mass, muscle strength, and overall functional performance. The composition is intended for oral administration and may be formulated in any suitable orally administrable dosage forms including but not limited to a tablet, capsule, powder, pill, hard capsule containing liquid or solid fill, soft capsule, granule, pellet, caplet, mini-tablet, gummy, syrup, suspension, sachet or a, modified-release formulation.

The application discloses a wheat Tilletia indica-specific biomarker combination, a screening method and application thereof, and the biomarker combination comprises 20-hydroxyarachidonic acid, 1-octadecyl lysophosphatidic acid, linolenic acid, 13-hydroxydocosahexaenoic acid, 4-methoxy estrone, hypoxanthine, 3-hydroxymyristic acid, beta-ecdysterone, 17-phenyltrinorprostaglandin F2 alpha cyclopropylmethylamide, 11,12-dihydroxyeicosatrienoic acid and oxidized octadecadienoic acid. When the biomarker combination is used for identifying Tilletia indica, the time-consuming long and the accuracy easily interfered by the spore development stage limitations of traditional morphological identification are overcome; in view of the molecular level identification difficulty caused by the high genome homology of Tilletia indica and Tilletia controversa, the application digs the feature difference at the level of metabolomics, and constructs a specific chemical fingerprint, so that the technical bottleneck that the close relatives are difficult to accurately distinguish is effectively solved.